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Triggering receptor expressed on myeloid cells 2
(TREM2) is a microglial surface receptor that triggers
intracellular protein tyrosinephosphorylation.Recent
genome-wide association studies have shown that a
rare R47H mutation of TREM2 correlates with a sub-
stantial increase in the risk of developing Alzheimer’s
disease (AD). To address the basis for this genetic as-
sociation,we studied TREM2deficiency in the 5XFAD
mousemodel of AD.We found that TREM2deficiency
and haploinsufficiency augment b-amyloid (Ab)
accumulation due to a dysfunctional response of mi-
croglia, which fail to cluster around Ab plaques and
become apoptotic. We further demonstrate that
TREM2 senses a broad array of anionic and zwitter-
ionic lipids known to associate with fibrillar Ab in lipid
membranes and to be exposed on the surface of
damaged neurons. Remarkably, the R47H mutation
impairs TREM2 detection of lipid ligands. Thus,
TREM2 detects damage-associated lipid patterns
associated with neurodegeneration, sustaining the
microglial response to Ab accumulation.
INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder with histopathological hallmarks of b-amyloid (Ab) pla-
ques and neurofibrillary tangles in the brain (Huang and Mucke,
2012; Tanzi, 2013). Although disease etiology is incompletely un-
derstood, families with inherited early-onset AD have mutations
in three proteins directly involved in the Ab processing pathway,
suggesting a key role for Ab in disease pathogenesis. Early
studies have shown that brain microglia accumulate around Ab
plaques and occasionally contain Ab in both AD patients (D’An-
drea et al., 2004;McGeer et al., 1987; Perlmutter et al., 1990) and
transgenic mousemodels of AD (Dickson, 1999; Frautschy et al.,
1998; Stalder et al., 1999). Microglia contribute to Ab clearance,
at least in the early phases of neurodegeneration (El Khoury et al.,2007); however, the ability of microglia to clear Abmaywanewith
age (Streit et al., 2004; Streit and Xue, 2009). At late stages of AD,
microglia may paradoxically contribute to the disease by
releasing pro-inflammatory cytokines in response to Ab deposi-
tion (El Khoury et al., 2007; Hickman et al., 2008).
Recent genome-wide association studies (GWASs) have
shown that a rare Arginine-47-Histidine (R47H) mutation of the
triggering receptor expressed on myeloid cells 2 (TREM2) is
associated with a substantial increase in the risk of developing
AD (Guerreiro et al., 2013b; Jonsson et al., 2013). TREM2 is a
cell-surface receptor of the Ig-superfamily that is expressed by
microglia andosteoclasts in vivo (Kiialainen et al., 2005; Paloneva
et al., 2002; Schmid et al., 2002; Thrash et al., 2009) as well as
monocyte-derived DCs, bone marrow-derived macrophages,
and macrophage cell lines in vitro (Bouchon et al., 2001; Daws
et al., 2001). Although TREM2 was detected in other cells of the
CNS (Guerreiro et al., 2013b; Sessa et al., 2004), these observa-
tions have not been confirmed (Jiang et al., 2014). TREM2 binds
anionic carbohydrates, anionic bacterial products, and various
phospholipids (Cannon et al., 2012; Daws et al., 2003). It trans-
mits intracellular signals through the associated transmembrane
adaptor DAP12, which recruits the protein tyrosine kinase Syk,
leading to phosphorylation of many downstream mediators,
such as PLC-g, PI-3K, and Vav2/3 (Ford and McVicar, 2009;
Peng et al., 2010). Individuals homozygous for rare mutations
that impair expression of either TREM2 or DAP12 develop lethal
forms of progressive dementias such as Nasu-Hakola disease
(NHD) and frontotemporal dementia (FTD) (Guerreiro et al.,
2013a, 2013c; Kleinberger et al., 2014; Paloneva et al., 2002).
The association between the R47H mutation of TREM2 and
the increased risk for late-onset AD suggests that microglia
may require TREM2 to respond to Ab deposition and to limit
neuronal degeneration. Consistent with this hypothesis, we
recently showed that APPPS1-21 transgenic mice, an AD model
with rapid deposition of Ab, have a marked decrease in the num-
ber and size of Ab-associatedmicroglia when they lack one copy
of the Trem2 gene, although this defect did not increase Ab
accumulation (Ulrich et al., 2014). The mechanisms underlying
this altered microglial response and its impact on Ab deposition
have not been delineated. To address these questions, we stud-
ied TREM2 deficiency in the 5XFADmousemodel of AD, in whichCell 160, 1061–1071, March 12, 2015 ª2015 Elsevier Inc. 1061
Figure 1. TREM2-Deficient 5XFAD Mice Have Increased Hippocampal Ab Burden and Accelerated Loss of Layer V Cortical Neurons
Ab burden in 8.5-month-old Trem2–/–5XFAD, Trem2+/–5XFAD, and 5XFAD mice.
(A) Matching coronal hippocampus and cortex sections were stained with an Ab-specific antibody mHJ3.4.
(B) Amounts of Ab loads in hippocampi.
(C–E) Soluble and insoluble Ab1-40 and Ab1-42 levels in hippocampi as detected by ELISA.
(F and G) Densities of layer V neurons in 8.5-month-old Trem2–/–5XFAD, Trem2+/–5XFAD, and 5XFAD mice. (F) Matching coronal sections stained with cresyl
violet. (G) Summary of densities of layer V neurons.
Original magnification: 103; scale bar, 100 mm. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, one-way ANOVA. Data represent analyses total of eight to ten
5XFAD mice, eight to 12 Trem2+/–5XFAD mice, and eight to 16 Trem2–/–5XFAD mice (B, C–E, and G). Bars represent mean ± SEM. See also Figure S1.Ab deposition develops less rapidly than in APPPS1-21 mice
(Oakley et al., 2006). We find that both TREM2 deficiency and
haploinsufficiency augment Ab accumulation due to a dysfunc-
tional response of microglia, which become apoptotic rather
than undergoing activation and proliferation. We further show
that TREM2 sustains microglial survival by synergizing with col-
ony stimulating factor-1 receptor (CSF-1R) signaling. Finally, we
demonstrate that TREM2 binds to a broad array of anionic lipids,
which were found in association with fibrillar Ab and are also
exposed during neuronal and glial cell death. Remarkably, the
R47H mutation impairs TREM2 binding to anionic lipids. We
conclude that TREM2 is a receptor that detects damage-associ-
ated lipids, thereby enabling microglia to sense Ab accumulation
and cell damage, as well as supporting microglial survival and Ab
reactive microgliosis.
RESULTS
TREM2 Modulates Ab Accumulation
We examined the deposition of Ab aggregates in Trem2–/– mice
bred to 5XFAD transgenic mice (APPSwFlLon, PSEN1*M146L*
L286V), an accelerated mouse model of AD (Oakley et al.,1062 Cell 160, 1061–1071, March 12, 2015 ª2015 Elsevier Inc.2006). Staining of matched coronal brain sections from
Trem2–/–5XFAD mice and control 5XFAD mice at 8.5 months
of age with a monoclonal antibody (mAb) against Ab revealed
significantly increased Ab accumulation in the hippocampal
but not cortical regions of Trem2–/–5XFAD mice (Figures 1A,
1B, and S1A). Trem2+/–5XFAD mice had an intermediate pheno-
type, although it was not statistically significant (p = 0.104). We
also determined levels of Ab40 and Ab42 in the hippocampus and
cortex of these mice by ELISA. While levels of soluble Ab40 and
Ab42 were similar (Figures 1C and S1B), we detected a signifi-
cant increase in insoluble, guanidine-extracted Ab40 and Ab42
in the hippocampal regions of Trem2–/–5XFAD mice compared
to 5XFAD mice (Figures 1D and 1E). Moreover, there was a sig-
nificant effect of Trem2 gene copy number on insoluble Ab pro-
tein levels in the hippocampi, whereas levels of insoluble Ab40
and Ab42 in the cortex were equivalent across all three geno-
types (Figures S1C and S1D). We also found that the loss of
layer V neurons, a feature of 5XFAD mice (Eimer and Vassar,
2013; Oakley et al., 2006), was more prominent in Trem2–/–
5XFAD mice (Figures 1F and 1G). Trem2+/–5XFAD mice pre-
sented an intermediate phenotype. Collectively, these data sug-
gest that TREM2 modulates Ab accumulation, limiting neuronal
loss. The lack of a significant difference in Ab accumulation in
the cortices of Trem2–/–5XFAD mice and 5XFAD mice may be
the result of the fast kinetics of Ab deposition in 5XFAD mice,
such that the potential cortical differences are no longer detect-
able at 8.5 month of age.
TREM2 Is Required for Reactive Microgliosis
How does lack of TREM2 impact Ab accumulation? Although
TREM2 expression has been reported in CNS cells other than
microglia (Guerreiro et al., 2013b; Sessa et al., 2004), this
finding is controversial (Jiang et al., 2014). Indeed, a recently
published RNA sequencing (RNA-seq) data set demonstrated
that Trem2 is specifically expressed in microglia, but not other
cells in the CNS under steady-state conditions (Butovsky
et al., 2014). We also found that Trem2 expression is further up-
regulated in microglia isolated from 5XFAD mice during Ab
deposition (Figures S2A and S2B). Thus, we focused our
studies on microglia. One of the many effects of Ab deposition
is the induction of reactive microgliosis, which involves the
expansion of microglia and conversion to an activated state
(Ransohoff and Cardona, 2010). Microgliosis predominantly in-
volves the proliferation of brain-resident microglia, with some
contribution from blood-borne monocytes and microglia
migrating from adjacent non-damaged brain areas (El Khoury
et al., 2007; Grathwohl et al., 2009; Malm et al., 2005; Mildner
et al., 2011; Simard et al., 2006; Stalder et al., 2005). To eval-
uate the impact of TREM2 deficiency on Ab-induced microglial
responses in 5XFAD mice, we examined transcriptional profiles
of microglia purified from 5XFAD and Trem2–/–5XFAD mice as
well as transgene negative wild-type (WT) and Trem2–/– litter-
mates (Figure S2A). To evaluate changes in global transcrip-
tomes, we first performed principle component analysis (PCA)
of the top 15% most variable transcripts. We noticed that WT
and Trem2–/– replicates clustered closely, suggesting a limited
impact of TREM2 deficiency in the steady state, which was
confirmed by a volcano plot comparing the two groups (Figures
2A and 2B). In contrast, 5XFAD microglial replicates were
dramatically different from WT replicates (Figure 2A), and a vol-
cano plot revealed that 5XFAD microglia expressed many more
transcripts including those associated with microglial activation
(MHC-II, CD11c), production of inflammatory cytokines (inter-
leukin-1b [IL-1b], tumor necrosis factor-a [TNF-a], IL-12, and
SPP1), and neurotrophic factors (insulin growth factor 1
[IGF-1] and VEGFA) (Figure 2C). Trem2–/–5XFAD microglia had
an intermediate behavior in the principle component analysis
compared to 5XFAD and WT microglia. To further interrogate
how TREM2 deficiency affected the microglial response to Ab
deposition, we selected the transcripts upregulated 2-fold be-
tween 5XFAD and WT microglia (Figure 2C) and compared
the expression of these transcripts among the entire data set.
We found that Trem2–/–5XFAD microglia failed to upregulate
these transcripts and behaved more similarly to WT microglia,
as shown by hierarchical clustering and expression-by-expres-
sion plots (Figures 2D and 2E). Flow cytometric analysis of iso-
lated microglia confirmed phenotypic changes in 5XFAD micro-
glia consistent with increased activation, including a marked
increase in cell size and strong upregulation of MHC-II,
CD11c, and CD11b (Figures S2C–S2G). We also confirmedincreased expression of inflammatory cytokine transcripts by
qPCR in whole-brain lysates of 5XFAD mice (Figures S2I–
S2L). However, in Trem2–/–5XFAD mice, these changes were
markedly attenuated (Figures 2D, 2E, and S2C–S2L). In fact,
Trem2–/–5XFAD microglia were phenotypically more similar to
WT microglia in steady state than 5XFAD microglia. Overall,
these results implied that TREM2 is required for reactive
microgliosis.
Microglia Fail to Colocalize with Ab Plaques in Trem2–/–
Mice
Initial staining of microglia in coronal brain sections with Iba-1 re-
vealed very similar distribution of microglia in Trem2–/–, Trem2+/–
and WT adult mice (Figures S3A–S3C). However, co-staining of
coronal brain sections from Trem2–/–5XFAD and 5XFAD mice
with Iba-1 and X-34, to visualize microglia and Ab plaques,
respectively, showed remarkable differences. We found that
Trem2–/–5XFAD mice had reduced Iba-1 reactivity both in the
hippocampi and cortices compared to 5XFAD mice (Figures
3A–3D). This was particularly evident in the areas surrounding
Ab plaques (Figures 3E and 3F; Movies S1, S2, and S3), suggest-
ing a preferential reduction of microgliosis near amyloid de-
posits. Trem2+/–5XFAD mice also had a partial reduction of am-
yloid-associated Iba-1 reactivity.
Examination of a second model of AD, APPPS1-21 mice
that have been bred to Cx3cr1GFP/+ mice in order to visualize
endogenous microglia, confirmed that complete TREM2 defi-
ciency results in a marked reduction of GFP+ microglial clus-
ters around Ab plaques (Figures S3D–S3F). This corroborates
our previous observation that TREM2 haploinsufficiency corre-
lates with fewer amyloid-associated microglia in APPPS1-
21xCx3cr1GFP/+ mice (Ulrich et al., 2014). Moreover, since
CX3CR1 marks brain-resident microglia (Ransohoff and Car-
dona, 2010), these results also suggest that TREM2 deficiency
primarily affects the response of brain-resident microglia
to Ab.
To further quantify the number ofmicroglia around Ab plaques,
we recorded the coordinates (x, y, and z) of all visible microglial
cell bodies and the location of Ab plaques in each z stack
confocal image and calculated the number of microglia within
30 mm radius of the plaques (defined as plaque-associated mi-
croglia) and non-plaque-associated microglia. While no statisti-
cally significant difference was observed among non-plaque-
associated microglia (Figure S4A), we noted a high degree of
microglial clustering around amyloid plaques in 5XFAD mice
(average 4.28 microglia per plaque), which gradually decreased
in Trem2+/–5XFAD mice (average 3.42 microglia per plaque) and
Trem2–/–5XFAD mice (average 2.36 microglia per plaque) (Fig-
ures 4A and 4B). To confirm the ‘‘negligence’’ of microglial re-
sponses to Ab in the absence of TREM2, we compared the
actual frequency of microglia per plaque to that obtained by
Monte Carlo simulations where the same numbers of microglia
and plaques observed in z stack images were positioned by
chance in each genotype (Figure S4B). The probability that
observed microglial frequencies per plaque fell outside of simu-
lated random frequencies was inversely proportional to Trem2
gene copy number (Figure 4C). Moreover, while 27.9% of micro-
glial distribution in 5XFAD mice with respect to Ab plaques wasCell 160, 1061–1071, March 12, 2015 ª2015 Elsevier Inc. 1063
Figure 2. TREM2 Deficiency Impairs Ab-Induced Transcriptional Program in Microglia
Transcriptional analysis of microglia isolated from hippocampi and cortices of 8.5-month-old Trem2–/–5XFAD, 5XFAD, Trem2–/–, and WT mice.
(A) Top 15% most variable transcripts were subjected to principle component analysis (PCA). Plot shows two-dimensional (PC2 versus PC3) comparison of
transcriptional changes in all classes analyzed. WT and Trem2–/– bone marrow-derived macrophages were used as references.
(B) Volcano plot comparing microglial transcripts in Trem2–/– and WT mice. Trem2 transcript is indicated.
(C) Volcano plot comparing microglial transcripts in 5XFAD and WT mice. Numbers in plots (B) and (C) indicate probes that are significantly upregulated or
downregulated (±2-fold, p < 0.05, Student’s t test). Representative transcripts are indicated.
(D and E) Visualization of Ab-induced changes in microglial transcripts from (C). (D) A heatmap displays hierarchical clustering of all samples analyzed. (E) A
scatterplot compares these transcriptional changes in Trem2–/–5XFAD and 5XFAD microglia. Representative transcripts are shown.
See also Figure S2.not explained statistically by chance, the frequency of non-
random microglial distribution was reduced to 9.5% in
Trem2–/– 5XFAD mice (Figure 4D).
Another feature of reactive microgliosis is morphological
transformation. In 5XFAD mice, plaque-associated microglia
showed morphological changes associated with microglial
activation, including a partial retraction and a slight hypertro-
phy of the microglial cell processes as well as an increase in
size (Figures 4E–4G). These changes in microglial morphology
were significantly attenuated in Trem2+/–5XFAD and Trem2–/–
5XFAD mice (Figures 4E–4G) and were paralleled by an
increased distance between microglia and the center of their
associated plaques (Figure 4H). Collectively, these data indi-
cate that TREM2 is essential for the microglial response to
Ab plaques.1064 Cell 160, 1061–1071, March 12, 2015 ª2015 Elsevier Inc.TREM2 Deficiency Affects Microglial Survival in 5XFAD
Mice
Why is TREM2 required for Ab reactive microgliosis? We first hy-
pothesized that TREM2may be necessary for Ab uptake andmi-
croglial activation. We initially investigated the impact of TREM2
deficiency on microglial activation in vitro. For this analysis, we
used primary microglia isolated from adult mice and expanded
in the presence of optimal amounts of CSF-1 and TGF-b (Fig-
ure S5A), as they closely resemble microglia in vivo (Butovsky
et al., 2014). TREM2 deficiency did not affect microglial expan-
sion, migration, or TNF-a secretion in response to Ab (Figures
S5B–S5D). In contrast, Trem2–/– microglia produced significantly
more TNF-a than WT microglia in response to lipopolysaccha-
ride (LPS), consistent with previous demonstrations that
TREM2 attenuates cytokine responses to certain TLR ligands
Figure 3. TREM2 Deficiency Leads to Reduced Microgliosis in 5XFAD Mice
Microgliosis in 8.5-month-old Trem2–/–5XFAD, Trem2+/–5XFAD, and 5XFAD mice.
(A and B) Matching coronal sections were stained with Iba-1 (red) for microglia and X-34 (green) for amyloid plaques. Representative z stack images with
maximum projection are shown.
(C and D) Quantification of total Iba-1 reactivity per high-power field (HPF) in hippocampi and cortices.
(E and F) Quantification of microgliosis associated with plaques of similar sizes in hippocampi and cortices.
Original magnification 203 (A, B, upper panels), 403 (A, B, lower panels); scale bar, 10 mm (A, B, upper panels), 50 mm (A, B, lower panels). *p < 0.05, **p < 0.01,
****p < 0.0001, one-way ANOVA. Data represent analyses of a total of eight of ten 5XFAD, eight of 12 Trem2+/–5XFADmice, and eight of 16 Trem2–/–5XFADmice.
Bars represent mean ± SEM. See also Figure S3 and Movies S1, S2, and S3.(Hamerman et al., 2006; Turnbull et al., 2006). Moreover, TREM2
deficiency had very little impact on microglial uptake of Ab ag-
gregates (Figure S5E; Movie S4) or their subsequent proteolytic
processing, as demonstrated by similar degradation of the intra-
cellular concentration of Ab after initial loading (Figure S5F).
Thus, TREM2 deficiency does not engender a direct defect in
phagocytosis of Ab.Previous studies have suggested that the CSF-1-CSF-1R
pathway promotes reactive microgliosis (Chitu and Stanley,
2006) and Ab clearance (Mitrasinovic et al., 2003); consistent
with this, CSF1-deficient osteopetrotic (op/op) mice are charac-
terized by increased deposition of Ab, scarcity of microgliosis
and neuronal loss (Kaku et al., 2003). We had previously demon-
strated that TREM2 signaling via its associated adaptor DAP12Cell 160, 1061–1071, March 12, 2015 ª2015 Elsevier Inc. 1065
Figure 4. TREM2 Deficiency Diminishes the Capacity of Microglia to Cluster around Ab Plaques
Frequencies of plaque-associated microglia in 8.5-month-old Trem2–/–5XFAD, Trem2+/–5XFAD, and 5XFAD mice were determined.
(A) Heatmap shows frequencies of microglia in relation to Ab plaques shown as white squares.
(B) Summary of frequencies of plaque-associated microglia in all analyzed genotypes.
(C andD)Microglial clustering around plaques in 5XFAD, Trem2+/–5XFAD, and Trem2–/–5XFADmicewere compared toMonte Carlo simulations that assume total
randomness between plaques andmicroglia. Probabilities that any given microglia-plaque cluster are non-random are shown in (C). Pie charts show frequencies
of microglia-plaque clusters that cannot be statistically explained as random (p < 0.05) (D).
(E) Morphology of plaque-associated microglia highlighting the shape of cell bodies (red) and primary processes (cyan).
(F–H) Plaque-associated microglia are analyzed for their surface area (cell body only), average length of primary processes, and distance from the center of
adjacent Ab plaque.
Original magnification: 203; scale bar, 15 mm. *p < 0.05, ***p < 0.001, ****p < 0.0001, one-way ANOVA. Data represent analyses of a total seven mice per group
(A–D) and a total of five mice per group (E–G). Bars represent mean ± SEM. See also Figure S4.synergizes with CSF-1R signaling to promote survival of macro-
phages (Otero et al., 2009, 2012). Specifically, TREM2/DAP12
were required to induce activation of the Syk tyrosine kinase
pathway downstream of CSF-1R (Otero et al., 2009; Zou et al.,
2008). Thus, we hypothesized that TREM2 may synergize with
CSF-1-CSF-1R signaling to sustain reactive microgliosis during
Ab deposition. We initially tested this hypothesis in vitro by
measuring the survival of adult primary microglial cultures from
WT and Trem2–/– mice in the presence of graded concentrations
of CSF-1 (10%, 1%, and 0.1% L-cell conditioned medium
[LCM]). While TREM2 deficiency did not affect viability at high
concentrations of CSF-1 (10% and 1%), Trem2–/– microglia
were markedly less viable thanWTmicroglia in 0.1%CSF-1 (Fig-
ures 5A–5C). We next purified microglia from Trem2–/–5XFAD
and 5XFAD mice and cultured them in medium containing low
levels of CSF-1 (0.1% LCM) for 5 days. Trem2–/–5XFADmicroglia
were significantly less viable than 5XFAD microglia (Figure 5D).
Since CSF-1R captures CSF-1 and targets it for degradation
(Stanley and Chitu, 2014), the reduced survival of Trem2–/– mi-
croglia at low CSF-1 concentrations may reflect a marked sus-
ceptibility of these cells to CSF-1 deprivation that occurs when
microglia consume a limited supply of CSF-1. Indeed, CSF-1R
blockade reduced viability of 5XFAD microglia, confirming that
the pro-survival effect of TREM2 cannot replace that of CSF-
1R, but only synergize with it (Figure 5D).1066 Cell 160, 1061–1071, March 12, 2015 ª2015 Elsevier Inc.To evaluate the impact of TREM2 deficiency on microglia
apoptosis in vivo, we analyzed coronal sections of Trem2–/–
5XFAD and 5XFAD mice by TUNEL staining. Markedly more
TUNEL+ microglia were evident in Trem2–/–5XFAD mice than
the very few observed in control 5XFAD mice (Figures 5E and
5F), corroborating a role for TREM2 in maintaining microglial
survival during reactive microgliosis. Consistent with this,
significantly fewer microglia were recovered from the cortices
and hippocampi of Trem2–/–5XFAD mice than from 5XFAD
mice (Figure 5G). We postulate that reactive microgliosis is
associated with increased CSF-1 uptake by CSF-1R and
degradation restricting CSF-1 range of action, such that micro-
glia in close proximity must compete for CSF-1. Because of
their inability to survive CSF-1 limitation, TREM2-deficient
microglia are incapable of sustaining reactive microgliosis and
undergo apoptosis rather than becoming activated and
expanding.
TREM2 Is a Sensor for Anionic and Zwitterionic Lipids
that Accumulate in the CNS during Ab Deposition
We next sought to identify the ligand(s) that trigger TREM2
signaling during Ab deposition. Since TREM2 binds anionic
carbohydrates, anionic bacterial products, and phospholipids
(Cannon et al., 2012; Daws et al., 2003), we focused on lipids
that have been shown to accumulate during Ab deposition and
Figure 5. TREM2 Promotes Microglial Survival Ex Vivo and In Vivo
(A–C) Adult primarymicroglia were culturedwith various concentration of CSF-1-containing L-cell medium (LCM). Viability ofmicroglia by PI staining (A andB) and
morphology (C) were assessed on day 3. Original magnification: 203 (main images) and 403 (insets); scale bar, 10 mm.
(D) Microglia were purified ex vivo from 5XFAD mice and cultured in 0.1% LCM with or without CSF-1R blocking antibody AFS98. Viability was determined on
day 5.
(E and F) Apoptosis of plaque-associated microglia (Iba-1, red) in 5XFAD and Trem2–/–5XFAD mice was determined by TUNEL staining (green). Plaques were
identified by X-34 (blue). Representative single-stack images of 5XFAD and Trem2–/–5XFAD microglia (E) and summary of frequencies of TUNEL+ microglia
associated with plaques (F) are shown. Original magnification: 203; scale bar, 15 mm (E).
(G) Total numbers of live microglia in cortices and hippocampi of 5XFAD, Trem2–/–5XFAD, Trem2–/–, and WT mice.
****p < 0.0001, two-way ANOVA (A, D, andG), Student’s t test (F). Data represent a total of three independent experiments (A–D) and a total of five to eightmice per
group (E–G). Bars represent mean ± SEM. See also Figure S5 and Movie S4.might stimulate microglia. These included negatively charged
phospholipids, which have been shown to associate with Ab
in lipid membranes (Ahyayauch et al., 2012; Nagarathinam
et al., 2013); membrane phospholipids, such as phosphatidyl-
serine, which are exposed by damaged neurons and glial cells;
and anionic and zwitterionic non-phosphate lipids, such as sul-
fatides and sphingomyelin, which are released by damaged
myelin. We transfected human TREM2 in reporter cells that ex-
press GFP under the control of NFAT, such that Ca2+ mobiliza-
tion turns on GFP expression when TREM2 is engaged. Incu-
bation of TREM2 reporter cells with many of these lipids
activated reporter activity, although to differing extents, with
phosphatidylcholine (PC) and sphingomyelin (SM) performing
best in these assays (Figures 6A and 6B). Similar results
were obtained with a mouse TREM2 reporter (data not shown).
Addition of a blocking TREM2 antibody abolished reporter acti-
vation by all ligands, demonstrating specificity (Figure 6B).
Interestingly, other potential candidates, such as cardiolipin,
which is released by damaged mitochondria, did not signifi-
cantly activate the TREM2 reporter despite its phospholipid
structure. This suggests that the ability to engage TREM2
may only partially depend on the presence of negatively
charged moieties like phosphoric acid (Figures 6A and 6B).
Furthermore, TREM2 reporter activation was not detected
with plate-bound synthetic or extracted Ab (data not shown).
In agreement with the ability of phosphotidylserine (PS) to acti-vate TREM2 reporter cells, apoptotic cells, which expose PS
on the cell surface, also activated TREM2 reporter cells (Fig-
ure 6C). However, microglia isolated from Trem2–/–5XFAD
and 5XFAD mice engulfed apoptotic cells equally well (Figures
6D and 6E). Thus, TREM2 is not directly involved in phagocy-
tosis of apoptotic cells. We conclude that TREM2 is a sensor
for several anionic and zwitterionic lipids that are exposed dur-
ing Ab deposition as well as during neuronal and glial cell
death.
R47H Mutation Impairs TREM2 Recognition of Lipid
Ligands
What is the impact of the R47H mutation on TREM2 ligand
recognition? We generated TREM2 R47H reporter cells and
compared their response to identified ligands to that of TREM2
reporter cells. The R47Hmutation considerably reduced reporter
activation in response to many ligands, including phosphatidic
acid (PA), phosphatidylglycerol (PG), PS, phosphatidylinositol
(PI), and sulfatides (Figures 7A–7G). The R47H mutation had
less impact on SM recognition and very little influence on PC-
mediated activation. Importantly, the R47H mutation did not de-
tectably affect cell-surface expression or signaling of TREM2, as
assessed by stimulating the R47H reporter cells with a plate-
bound anti-TREM2 antibody (Figure 7H). Thus, these data sug-
gest that the R47H reduces the overall capacity of TREM2 to
bind anionic ligands.Cell 160, 1061–1071, March 12, 2015 ª2015 Elsevier Inc. 1067
Figure 6. TREM2 Is a Receptor for Lipid Patterns Associated with Ab
(A and B) Human TREM2 reporter cells were stimulated with various phospholipids and anionic and zwitterionic lipids at the indicated concentrations. Reporter
activation (GFP expression) was assessed after overnight incubation by flow cytometry. TREM2 reporter cells responding to lipids at various concentrations are
shown in (A). Blockade of reporter activation by a soluble anti-hTREM2 mAb is shown in (B). SM, sphingomyelin; PA, phosphatidic acid; PI, phosphatidylinositol;
PC, phosphatidylcholine; PG, phosphatidylglycerol; PS, phosphatidylserine; Sulf, sulfatide; and CL, cardiolipin.
(C) mTREM2 reporter cells were cultured with either apoptotic cells (AC) or phosphatidylserine (PS) in the presence of soluble anti-TREM2mAb or isotype control.
(D and E) Adult primary microglia from Trem2–/–5XFAD and 5XFADmice were pulsed with CSFE-labeled AC. (D) Phagocytosis of AC was determined 20, 40, and
60 min post co-culturing by flow cytometry. (E) Summary of AC uptake by WT and Trem2–/– microglia.
Data represent a total of three (A–C) and two (D and E) independent experiments.DISCUSSION
This study showed that TREM2 modulates Ab accumulation in
the 5XFADmouse model of AD, thereby reducing neuronal dam-
age. The importance of TREM2 in Ab clearance is underscored
by the fact that even the loss of one copy of Trem2 gene is suf-
ficient to increase Ab accumulation. TREM2 acts in microglia by
supporting Ab-reactive microgliosis, a process of expansion and
activation that leads to microglial clustering around Ab plaques
and subsequent Ab removal (Ransohoff and Cardona, 2010). In
the absence of TREM2, this microgliosis is impaired. In fact, mi-
croglia from Trem2–/–5XFAD mice are unable to survive, as evi-
denced by the accumulation of apoptotic microglia around Ab
plaques. Cells involved in TREM2-dependent microgliosis had
phenotypic features of brain resident microglia, such as expres-
sion of CX3CR1. However, it is possible that monocytes from
peripheral blood contribute to microgliosis and that TREM2 sup-
ports their survival as well.
Previous studies have shown that CSF-1-CSF-1R signaling is
essential for microgliosis in response to Ab (Chitu and Stanley,
2006; Kaku et al., 2003; Mitrasinovic et al., 2003). Since CSF-1
is rapidly consumed during this process (Stanley and Chitu,
2014), there is probably a limited supply of CSF-1 surrounding1068 Cell 160, 1061–1071, March 12, 2015 ª2015 Elsevier Inc.the Ab plaques. Our results demonstrate that TREM2 provides
a signal that is necessary for survival of microglia at low CSF-1
concentrations. We postulate that TREM2 acts as a costimula-
tory molecule that sustains survival of microglia, which are acti-
vated and proliferate in the presence of Ab. Previous studies of
cultured myeloid cells indicate that TREM2 may synergize with
CSF-1-CSF-1R signaling to activate the protein tyrosine kinase
Syk, which, in turn, activates multiple downstream mediators,
such as ERK, PI-3K, and Akt (Zou et al., 2008). In addition,
TREM2 may provide survival signals through activation of anti-
apoptotic mediators such as b-catenin (Otero et al., 2009) and
Mcl-1 (Peng et al., 2010). It is also possible that TREM2 is
necessary to support increased microglial metabolism during
activation.
Why is TREM2 activated during Ab accumulation? Previous
studies have indicated that TREM2 binds phospholipids,
such as PS, and acts as a scavenger receptor for apoptotic
cells that might be generated during neuronal damage (Hsieh
et al., 2009; Takahashi et al., 2005, 2007). In our study, we
demonstrate that TREM2 is a sensor for a broad array of acidic
and zwitterionic lipids, which may or may not contain a
phosphoric acid moiety. Membranes containing these lipids
strongly interact with Ab, facilitating the formation of fibrillar Ab
Figure 7. R47H Mutation Attenuates TREM2 Recognition of Lipids
(A–H) Reporter cells expressing either common allele or R47H variant of human TREM2 were stimulated with various species of lipids or plate-bound anti-
hTREM2 mAb. A plate-bound control antibody (anti-hTREML2) was used as a negative control. Data represent a total of two independent experiments. Bars
represent mean ± SEM.(Ahyayauch et al., 2012; Del Mar Martı´nez-Senac et al., 1999;
Nagarathinam et al., 2013). Moreover, some TREM2 lipidic
ligands accumulate on the cell surface of neurons and glial cells
damaged by Ab accumulation, such as PS (Eckert et al., 2005;
McLaurin and Chakrabartty, 1996), or are released by damaged
myelin, such as SM and sulfatides. In contrast, TREM2 did not
directly bind Ab. Consistent with its ability to bind anionic lipids,
the TREM2 extracellular domain is rich in arginine residues that
may form salt bridges with polyanions. Remarkably, we found
that the R47H mutation associated with AD affected the binding
of multiple lipid ligands, although to differing extents. Most likely,
the R47H mutation is sufficient to considerably reduce the bind-
ing affinity of TREM2 extracellular domain for most anionic
ligands. Structural studies will be essential to validate this model.
Our findings demonstrated that TREM2 functions as a micro-
glial sensor that is alerted by damage-induced molecules that
share a common lipidic backbone and an anionic group. In
contrast with previous reports (Hsieh et al., 2009; Takahashi
et al., 2005, 2007), we found that the engagement of TREM2
does not directly mediate phagocytosis of apoptotic cells. How-
ever, TREM2 signaling may indirectly support phagocytosis by
promoting survival of activated microglia. It has been shown
that individuals homozygous for rare mutations that impair
expression of either TREM2 or DAP12 develop lethal forms of
progressive, early-onset dementia such as Nasu-Hakola disease
(NHD) and frontotemporal dementia (Guerreiro et al., 2013a,
2013c; Kleinberger et al., 2014; Paloneva et al., 2002). Although
the pathology of these forms of dementia differs from that of AD
and often involves demyelination, our study suggests that
TREM2 may be required for microglia to sense glycolipids
such as SM and sulfatides that are exposed on damaged myelin
sheaths; thus, TREM2 binding to these glycolipids may trigger
the microglial response to damaged myelin, which is necessary
to clear myelin residues and produce trophic factors that inducerepair and remyelination. While the R47H mutation associated
with AD did not entirely abolish ligand binding, mutations asso-
ciated with Nasu-Hakola disease result in a complete lack of
TREM2 expression (Kleinberger et al., 2014), which may explain
the distinct pathology and more dramatic clinical course of this
disease.
EXPERIMENTAL PROCEDURES
Mice
Trem2–/– mice were generated as previously described. 5XFADmice were pur-
chased from the Jackson Laboratory (MMRRC) and crossed to Trem2–/– mice
to generate Trem2+/–5XFAD and Trem2–/–5XFADmice. All mice were bred and
housed in the same animal facility. Trem2–/–Cx3cr1+/GFPAPPPS1-21micewere
generated in a similar manner, as previously described (Ulrich et al., 2014). All
animal studies were approved by the Washington University Animal Studies
Committee.
Preparation of Brain Samples
For histological analysis 5XFAD mice, APPPS1-21 and transgene negative
controls were anesthetized with ketamine and perfused with ice-cold PBS.
Right-brain hemispheres were fixed in 4% PFA overnight and placed in 30%
sucrose before freezing and cutting on a freezing sliding microtome. Serial
40-mm coronal sections of the brain were collected from the rostral anterior
commissure to caudal hippocampus as landmarks. For biochemical and
mRNA expression analysis, cortices and hippocampi of the left-brain hemi-
spheres were carefully dissected out and flash frozen in liquid nitrogen.
Immunohistochemistry and Microscopy
For detailed procedures, see Extended Experimental Procedures.
Gene Expression Analysis
For frozen brain tissues, RNA was extracted using a RNeasy mini kit according
to manufacture protocol (QIAGEN). Microglia were fluorescence-activated
cell-sorted (FACS) directly into RLT-plus lysis buffer, and RNA extraction
was performed using a RNeasy micro kit according to manufacture protocol
(QIAGEN). Primers for qPCR analysis are provided in Table S1. For detailed
procedure on microarray analysis, see Extended Experimental Procedures.Cell 160, 1061–1071, March 12, 2015 ª2015 Elsevier Inc. 1069
ELISA
Ab levels were assessed using sandwich ELISAs as described (Kim et al.,
2009). For detailed procedure, see Extended Experimental Procedures.
Ex Vivo Microglia Cultures
Primary adult microglia culture was generated as previously described (Butov-
sky et al., 2014). Briefly, purified adult microglia were cultured in the presence
of 15% LCM media (Otero et al., 2009) and 10 ng/ml human TGF-b1 (Pepro-
Tech) for 7 days before experiments. For details on in vitro assays performed,
see Extended Experimental Procedures.
Reporter Assay
2B4 GFP-NFAT reporter T cells were stably transfected with murine or human
TREM2 cDNAs. Cells were cultured with apoptotic thymocytes in round-bot-
tom 96-well plates or plated onto high-absorbance flat-bottom plate coated
with various lipids at indicated concentration. Reporter cells were assessed af-
ter overnight incubation. Reporter activity (%) is defined as %GFP+ cells sub-
tracted from background (vehicle controls).
Statistics
Data in figures are presented as mean ± SEM. All statistical analysis was per-
formed using Prism (GraphPad). Statistical analysis to compare the mean
values for multiple groups was performed using a one-way or two-way
ANOVA with correction for multiple comparisons. Comparison of two groups
was performed using a two-tailed unpaired t test (Mann-Whitney). Values
were accepted as significant if p% 0.05.
ACCESSION NUMBERS
All data have been deposited at GEO (GSE65067).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
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